T. Ishida et al. / Bioorg. Med. Chem. Lett. 16 (2006) 1859–1863
1863
8. (a) Another group, Boehringer Ingelheim, also indepen-
dently discovered benzimidazole derivatives as NS5B
inhibitors: Beaulieu, P. L.; Fazal, G.; Gillard, J.;
Kukolj, G.; Austel, V. Patent WO-0204425, 2002; (b)
Beaulieu, P. L.; Bo¨s, M.; Bousquet, Y.; Fazal, G.;
Gauthier, J.; Gillard, J.; Goulet, S.; LaPlante, S.;
Poupart, M.-A.; Lefebvre, S.; McKercher, G.; Pellerin,
C.; Austel, V.; Kukolj, G. Bioorg. Med. Chem. Lett.
2004, 14, 119; (c) Beaulieu, P. L.; Bo¨s, M.; Bousquet,
Y.; Deroy, P.; Fazal, G.; Gauthier, J.; Gillard, J.;
Goulet, S.; McKercher, G.; Poupart, M.-A.; Valois, S.;
Kukolj, G. Bioorg. Med. Chem. Lett. 2004, 14, 967; (d)
Beaulieu, P. L.; Bousquet, Y.; Gauthier, J.; Gillard, J.;
Marquis, M.; McKercher, G.; Pellerin, C.; Valois, S.;
Kukolj, G. J. Med. Chem. 2004, 47, 6884.
studies including the effect of substituents other than F
atom on the central phenyl ring are on the way and will
be reported in due course.
Acknowledgments
We thank Mr. Mitsumasa Takahashi and Mr. Eita
Nagao for analytical support. We are grateful to
Mr. Yasushi Niwa and Mr. Masakazu Komatsu for
support running the biological assays.
Supplementary data
9. (a) Recently, structurally related indole derivatives were
reported from several groups: Beaulieu, P. L.; Fazal, G.;
Goulet, S.; Kukolj, G.; Poirier, M.; Tsantrizos, Y. S.;
Jolicoeur, E.; Gillard, J.; Poupart, M.-A; Rancourt, J.
Patent WO-2003010141, 2003; (b) Harper, S.; Pacini, B.;
Avolio, S.; Di Filippo, M.; Migliaccio, G.; Laufer, R.; De
Francesco, R.; Rowley, M.; Narjes, F. J. Med. Chem.
2005, 48, 1314; (c) Oka, T.; Yata, S.; Ikegashira, K.; Noji,
S.; Akaki, T.; Hirashima, S.; Niwa, Y.; Ando, I.; Sato, T.
Patent WO-2005014543, 2005; (d) Harper, S.; Avolio, S.;
Pacini, B.; Di Filippo, M.; Altamura, S.; Tomei, L.;
Paonessa, G.; Di Marco, S.; Carfi, A.; Giuliano, C.;
Padron, J.; Bonelli, F.; Migliaccio, G.; De Francesco, R.;
Laufer, R.; Rowley, M.; Narjes, F. J. Med. Chem. 2005,
48, 4547.
Supplementary data associated with this article can be
References and notes
1. Lauer, G. M.; Walker, B. D. N. Eng. J. Med. 2001, 345,
41.
2. World Health Organization Weekly Epidemiological Record
2000, 75, 18.
3. (a) Tan, S.-L.; Pause, A.; Shi, Y.; Sonenberg, N. Nat. Rev.
Drug Disc. 2002, 1, 867; (b) Poynard, T.; Yuen, M.-F.;
Ratziu, V.; Lai, C. L. Lancet 2003, 362, 2095.
4. Manns, M. P.; McHutchison, J. G.; Gordon, S. C.; Rustgi,
V. K.; Schiffman, M.; Reindollar, R.; Goodman, Z. D.;
Koury, K.; Ling, M.-H.; Albrecht, J. K. Lancet 2001, 358,
958.
5. Poynard, T.; Macrellin, P.; Lee, S. S.; Niederau, C.;
Minuk, G. S.; Ideo, G.; Bain, V.; Heathcote, J.; Zeuzem,
S.; Trepo, C.; Albrecht, J. Lancet 1998, 352, 1426.
6. NS5B inhibitors are summarized in the following reviews
(a) Gordon, C. P.; Keller, P. A. J. Med. Chem. 2005, 48, 1;
(b) Beaulieu, P. L.; Tsantrizos, Y. S. Curr. Opin. Invest.
Drugs 2004, 5, 838; (c) De Francesco, R.; Tomei, L.;
Altamura, S.; Summa, V.; Migliaccio, G. Antiviral Res.
2003, 58, 1.
10. Kamel, M.; Allam, M. A.; Abou-Zeid, N. Y. Tetrahedron
1967, 23, 1863.
11. Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457.
12. Thomas, P. R.; Tyler, G. J. J. Chem. Soc. 1958, 2197.
13. Adachi, T.; Ago, H.; Habuka, N.; Okuda, K.; Komatsu,
M.; Ikeda, S.; Yatsunami, K. Biochim. Biophys. Acta 2002,
1601, 38.
14. (a) Lohmann, V.; Ko¨rner, F.; Koch, J. O.; Herian, U.;
Theilmann, L.; Bartenschlager, R. Science 1999, 285, 110;
(b) Krieger, N.; Lohmann, V.; Bartenschlager, R. J. Virol.
2001, 75, 4614.
15. The same observation was seen in the case reported by
Boehringer Ingelheim Ltd. See Ref. 8b.
16. The biphenyl type of compounds 24e is also attractive
for further study. The results will be reported in due
course.
7. Hashimoto, H.: Mizutani, K.; Yoshida, A. Patent WO-
0147883, 2001.